Purpose To determine the pharmacokinetics, tissue, and blood distribution of rapamycin PEG-block-poly( -caprolactone) (PEG-b-PCL) micelle formulations with and without the addition of -tocopherol compared to control rapamycin in Tween 80/PEG 400/N,N-dimethylacetamide (DMA) (7:64:29). Methods Rapamycin was incorporated at 10% w/w into PEG-b-PCL micelles (5:10 kDa) using a solvent extraction technique. The co-incorporation of 2:1 -tocopherol:PEGb-PCL was also studied. Rapamycin was quantiWed utilizing LC/MS in a Waters XTerra MS C18 column with 32-desmethoxyrapamycin as the internal standard. Male Sprague Dawley rats (N = 4 per group; »200 g) were cannulated via the left jugular and dosed intravenously (IV) with the rapamycin control and micelle formulations (10 mg/kg, 1:9 ratio for rapamycin to PEG-b-PCL). For tissue distribution 24 h after IV dosing, whole blood, plasma, red blood cells, and all the representative tissues were collected. The tissues were rapidly frozen under liquid nitrogen and ground to a Wne powder. The rapamycin concentrations in plasma and red blood cells were utilized to determine the blood distribution (partition coeYcient between plasma and red blood cells). For the determination of the pharmacokinetic parameters, blood, plasma, and urine samples were collected over 48 h. The pharmacokinetic parameters were calculated using WinNonlin® (Version 5.1) software. Results Rapamycin concentrations were considerably less in brain after administration of both micelle formulations compared to a rapamycin in the Tween 80/PEG 400/DMA control group. There was a 2-fold and 1.6-fold increase in the plasma fraction for rapamycin micelles with and without -tocopherol. There was a decrease in volume of distribution for both formulations, an increase in AUC, a decrease in clearance, and increase in half life respectively for rapamycin in PEG-b-PCL + -tocopherol micelles and in PEG-b-PCL micelles. There was no mortality with the micelle formulations compared to 60% mortality with rapamycin in Tween 80/PEG 400/DMA. Conclusions The decreased distribution into the brain of rapamycin in PEG-b-PCL micelles may ameliorate rapamycin neurotoxicity. Both micelle formulations increase rapamycin distribution in plasma, which could facilitate access into solid tumors. The micellar delivery systems of rapamycin impart in vivo controlled release, resulting in altered disposition, and dramatically reduced mortality.
Introduction
Rapamycin (Sirolimus) (Fig. 1a) is a large (MW 914 g/mol) lipophilic (X log P O/W 5.77) carboxylic lactone-lactam macrolide antibiotic that was Wrst isolated from the soil bacteria Streptomyces hygroscopicus from the soil of the Vai Atari region of Rapa Nui (Easter Island, Chile) more than 25 years ago [39] . It was originally developed as an antifungal agent [10, 25] , but posterior investigations reported its potent antiproliferative and immunosuppressive eVects in vitro [14, 27, 32, 34] and in vivo [25, 28, 46] allowing it to be currently utilized as conjunction therapy with cyclosporine A in kidney and liver transplant recipients [31] . Further investigations also revealed that rapamycin has a unique anti-tumor mechanism through the binding with FKBP12 and the inhibition of mammalian target of rapamycin (mTOR), which is a central regulator of proliferation, apoptosis [5, 11, 37, 41] , and cell growth by inducing cell-cycle arrest in the G 1 phase [7] . These latter pharmacological properties have allowed rapamycin to be recognized recently as a possible chemotherapeutic agent against many solid tumor types including breast [21] , colon [15] , prostate [50] , and renal cell carcinomas [38] with a typical IC 50 < 50 nM.
Even though rapamycin oVers promising pharmacological activities, it faces two major pharmacokinetic limitations. First, the clinical development of rapamycin has been hindered by its poorly water soluble (2.6 g/ml) behavior [34, 40] making previous attempts to develop intravenous (IV) formulations diYcult [43] but still allowing the development of the currently employed oral solution and tablet forms [30] . However, rapamycin has a low oral bioavailability (<15%) [35, 45, 49] limiting the development of tablet formulations except for low-dosage treatments such as immunosuppression in renal and liver transplant recipients [31] . Furthermore, this low bioavailability has been related to rapamycin sensitivity to gastric acid, partial intestinal absorption, and mainly Wrst-pass hepatic metabolism (less than 3% excreted in urine) [24] . The second limitation is the strong partition of rapamycin to erythrocytes, cells, and tissue with red blood cell to plasma ratios of 36/1 or plasma to red blood cell ratio (K d ) of ca. 0.05, which may hinder accessibility into solid tumor sites [45, 46, 49] . Rapamycin exhibits a preferential distribution into red blood cells (94.5%) compared to plasma (3.1%), lymphocytes (1.01%) and granulocytes (1.0%) [30, 48] . Furthermore, this strong uptake and sequestration of rapamycin into red blood cells (RBC) can be partially explained by the high content of immunophillins [26] and lipoproteins [23] in RBC. The strong partition into cells and tissues can be attributed to two factors. The lipophilic nature of rapamycin allows it to be widely distributed into lipid membranes in the body as well as inducing its extensive apparent volume of distribution (5.6-16.7 l/kg) [17, 30, 49] of rapamycin. The extensive tissue distribution of rapamycin has been conWrmed by studies performed in rats where tissue to blood partition coeYcients (Kp) were reported to be more than 40 [35] . However, these partitioning determinations have not been performed in humans and the relationship between the concentration of rapamycin in tissues and the eYctive and toxic eVects of rapamycin is currently unknown. A single report demonstrated that rapamycin induces toxic eVects on brain cell metabolism in vitro [42] , but these observations have not yet been reported clinically. Therefore, a better understanding of the tissue distribution of rapamycin is warranted to try to establish a plausible relationship between its toxic eVects and biodistribution. Furthermore, this extensive partitioning into tissues provides a relatively long half-life of more than 5 h up to 87 h [9, 22, 24] that permit once-a-day dosing, a delay in reaching steady-state concentrations [24, 51] , a wide inter-and intra-patient variability in drug clearance (0.090-0.339 l/h kg) [9, 17, 24] and a less than optimal correlation between blood or plasma concentrations and dose [30] .
It is because of these limitations that diVerent approaches have been taken to improve the formulation and delivery of rapamycin. One of these approaches has been the development of Temsirolimus (CCI-779), a water-soluble rapamycin ester that has demonstrated promise in early Phase-I trials [1] . However, CCI-779 still has limited solubility in water, »120 g/ml, requiring the use of ethanol as a co-solvent [36] for IV formulations [33] . Moreover, phase-I trials have demonstrated that the CCI-779 prodrug is rapidly hydrolyzed by plasma esterases back into rapamycin and can thus redistribute and partition into blood erythrocytes [36, 49] , which may reduce accumulation into solid tumor sites. Even though, phases I and II clinical studies have reported signiWcant changes in the pharmacokinetic proWle (5-fold increase in C max , 5-fold decrease in t max , 3-fold decrease in t 1/2 , and 1-fold decrease in AUC) [20, 36] , high inter-patient variability and mild to moderate side eVects such as neurotropenia, thrombocytopenia, diarrhea, manic-depressive syndrome, and diarrhea were observed [20, 36] . Furthermore, some of the side eVects were exacerbated compared to the observed side eVects after rapamycin administration: headache and abdominal pain [16, 44] , skin disorders, nocturnal calf cramps, and muscle aching [18] . Therefore, the necessity to explore other formulation alternatives to improve the pharmacokinetic and biodistribution proWle, diminish the preferential partition of rapamycin into erythrocytes, and reduce some of the toxic side-eVects is warranted.
The therapeutic utility of rapamycin could be optimized by novel nanoformulated PEG-b-poly( -caprolactone) micelle delivery into solid tumors. These nanoparticle polymeric micelle delivery systems may optimally accumulate at solid tumors by the enhanced permeability and retention (EPR) eVect. Therefore, in the present studies, we optimized the incorporation of rapamycin into PEG-b-PCL micelles, which we have previously reported to eVectively encapsulate rapamycin [19] . Rapamycin loaded PEGb-PCL micelles were prepared using a scalable solventextraction technique that resulted in high drug loading, good stability, and extended release [19] . The present study has the objective to determine the pharmacokinetics, tissue and blood distribution, and assess any observable toxicities after administration of rapamycin PEG-block-poly( -caprolactone) (PEG-b-PCL) (Fig. 1b) micelle formulations with and without the addition of -tocopherol (Fig. 1c) compared to control rapamycin in Tween 80/PEG 400/ N,N-dimethylacetamide (DMA) (7:64:29).
Materials and methods

Rapamycin formulation in PEG-b-PCL micelles
Rapamycin loaded PEG-b-PCL micelles were prepared by a solvent extraction technique as previously described [19] . Poly(ethylene glycol)-block-poly( -caprolactone) (PEGb-PCL) (5,000:10,500, M w /M n 1.18, JCS Biopolytech, Toronto, Ontario) and rapamycin (LC Laboratories, Woburn, MA) were dissolved in a minimum volume of acetone and added drop-wise to vigorously stirred ddH 2 O using a syringe pump. The organic solvent was removed by stirring under an air purge. After removing the organic solvent, PEG-b-PCL micelle solutions were made up to 5% w/v dextrose and passed through a 0.22-m polyestersulfone Wlter to remove unincorporated drug and enable sterilization. Solutions were protected from light and stored at 4°C, protected from freezing, until administered to rats. Micelles containing -tocopherol (Sigma Chemical Co., St. Louis, MO, USA) were made in the same manner, with the addition of 10:1 -tocopherol:PEG-b-PCL (mol : mol) to the organic phase [19] . In a typical experiment, 12.5 mg rapamycin and 112.5 mg PEG-b-PCL (1:9 w/w) were dissolved in 1 ml of acetone and added (50 l/min) to 6 ml of ddH 2 O. The resulting clear solution was air purged to ca. 3 ml and made up to 6.25 ml (2 mg/ml rapamycin Wnal). The drug solution was made isotonic with 300 mg dextrose (5% w/v) and then Wlter-sterilized. All rapamycin and PEG-b-PCL formulations in this study, with and without tocopherol, were 1:9 w/w rapamycin to PEG-b-PCL, i.e. 1 mg/kg rapamycin and 9 mg/kg PEG-b-PCL.
The incorporation of rapamycin into PEG-b-PCL micelles was veriWed by equivalent retention times in ultraviolet (UV) and refractive index (RI) chromatographs from gel permeation chromatography. PEG-b-PCL micelles were injected on an OHpak SB-806M GPC column (20 l injections, 0.5 mM PEG-b-PCL, 0.75 ml/min of 10 mM HEPES eluent, pH 7.0, 30°C) (Shodex, Kawasaki, Japan) and detected by RI and UV absorbance (277 nm). Rapamycin loading into PEG-b-PCL micelles was quantitatively determined by reverse-phase HPLC (Ace 3-m C18 4.6 £ 50 mm) using a 50 mM acetic acid-MeOH gradient (25:75-0:100, 50°C, 277 nm detection). Hydrodynamic diameters of PEG-b-PCL micelles were determined by dynamic light scattering (DLS) (NICOMP 380 ZLS, Particle Sizing Systems, Santa Barbara, CA). Data were analyzed by intensity-weighted Gaussian distribution Wtting (NICOMP Version 1.76). Measurements were made for a minimum of 15 min or at least 1 £ 10 6 counts in channel 1. A control formulation for IV administration of rapamycin was made by dissolving rapamycin in DMA (1% w/v) and adding to a solution of PEG 400 and Tween 80 (Wnal 29:64:7 DMA:PEG:Tween), based on the rodent pharmacokinetics and distribution studies by Kahan et al. [6, 35] . In a typical experiment, 15 mg rapamycin was completely dissolved in 1.5 ml DMA, and added to a premixed solution of 3.375 ml PEG 400 and 0.375 ml Tween 80. The resulting mixture was vortexed until clear and passed through a 0.45-m PTFE syringe Wlter (Wnal 2.8 mg/ml rapamycin). The concentration of rapamycin was veriWed by reverse-phase HPLC as above.
Measurement of rapamycin concentrations in blood, plasma, urine, and tissue samples by LC/MS The protocol previously described by Annesley and Clayton [4] was slightly modiWed. For our purpose, 100 l of whole blood, plasma, calibrator or control, or 100 mg of tissue was added in a regular polypropylene microcentrifuge tube. Then, 250 l of deionized water, 250 l of aqueous 0.1 M zinc sulfate, and 500 l methanol containing the internal standard (32-desmethoxyrapamycin) were added. The mixture was vortexed for 30 s, and the tubes were left at room temperature for 4 min. Then, the tubes were centrifuged for 4 min, and the colorless supernatant was injected into the LC/MS system. The analyses were carried out on an Agilent 1100 Series LC/MSD. In the positive-ion mode the monitored single plot transitions (m/z) were: rapamycin 936!937, and 32-desmethoxyrapamycin 816!906. Separation was performed with a Waters XTerra MS C18 2.1 £ 100 mm column maintained at 40°C. The injection volume was 20 l with a Xow rate of 0.4 ml/min. The mobile phases were: (A) 2 mM ammonium acetate and 0.1% formic acid in water, (B) 2 mM ammonium acetate and 0.1% formic acid in methanol, and (C) acetonitrile. The gradient program was 50% A and 50% B for 0.10 min, followed by an immediate change to 10% A and 90% B at 0.11 min. At 1.80 min, the mobile phase was increased from 90% B to 100% B, and at 6.10 min, the mobile phase was changed to 100% C to clean the column. At 9.10 min, the mobile phase reverted to 50% A and 50% B. Rapamycin eluted at ca. 4.46 min and 32-desmethoxyrapamycin eluted at ca. 5.50 min. For quantiWcation in tissues, concentration ranges of 0.001-10 g/ml were employed in the calibration samples. For blood, plasma, and urine, the calibration samples were prepared at a concentration of 0.001-50 g/ml. For all runs, quality control samples were incorporated to ensure the integrity of the results. Standard curves were linear (R 2 = 0.999) and bias and precision data were less than 10%. The recovery was determined by enriching rat blood, plasma, urine, and tissue extract samples with rapamycin (0.05, 0.5, and 5 g/ml), and comparing the peak areas of the extracted samples to the areas obtained for injections of drug in saline (corrected for volume or dilution). It was observed that the recoveries for the diVerent biological matrices ranged from 94 to 97%, which are comparable results to previous studies [4, 13] .
Surgical procedures
Male Sprague-Dawley rats (200-240 g) were obtained from Simonsen Labs (Gilroy, CA, USA) and given food (Purina Rat Chow 5001) and water ad libitum in our animal facility for at least 3 days before use. Rats were housed in temperature-controlled rooms with a 12 h light/ dark cycle. The day before the pharmacokinetic experiment the right jugular veins of the rats were catherized with sterile silastic cannula (Dow Corning, Midland, MI, USA) under halothane (Sigma Chemical Co. St. Louis, MO, USA) anesthesia. This involved exposure of the vessel prior to cannula insertion. After cannulation, the Intramedic PE-50 polyethylene tubing (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) connected to the cannula was exteriorized through the dorsal skin. The cannula was Xushed with 0.9% saline. The animals were transferred to metabolic cages and were fasted overnight. Animal use protocols were approved by The Institutional Animal Care and Use Committee at Washington State University, in accordance with "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985).
Pharmacokinetic study
To assess the eVect of formulation on the pharmacokinetic parameters, rats were cannulated as described above and dosed intravenously with rapamycin (10 mg/kg) dissolved in DMA, PEG, and Tween 80 (control formulation); in PEG-b-PCL formulation (1 mg/kg rapamycin and 9 mg/kg polymer); or in PEG-b-PCL co-incorporated with -tocopherol (PEG-b-PCL + -tocopherol formulation) (n = 4 for each treatment group). The rats were given between 0.5 and 1 ml of each formulation as IV bolus within 5 min. After dosing, serial blood samples (»0.30 ml) were collected from the cannula at 0, 1, and 30 min, then 1, 2, 4, 6, 12, 24, and 48 h after IV administration, and the cannula Xushed with 0.9% saline. After dosing and after each serial blood sampling, blinded observers were present to record any visible behavior, bleeding, or overall appearance of the animal as signs of acute toxicity. Each blood sample was divided into one 0.1 ml fraction and one 0.2 ml fraction, the Wrst fraction (0.1 ml) was collected into regular polypropylene microcentrifuge tubes and labeled as blood sample and stored at ¡70°C until further LC/MS analysis. The second fraction (0.2 ml) was collected in heparanized tubes (Monoject, MansWeld MA) and following centrifugation, the plasma and red blood cell (RBC) fractions were collected and stored at ¡70°C until analyzed. Urine samples were also collected at 0, 2, 6, 12, 24, 24, and 48 h following IV administration and were stored at ¡70°C until analyzed.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed using data from individual rats for which the mean and standard error of the mean (SEM) were calculated for each group. The elimination rate constant (KE) was estimated by linear regression of the blood or plasma concentrations in the log-linear terminal phase. In order to estimate the blood or plasma concentrations (C 0 ) immediately after rapamycin IV dosing, a two-compartmental model was Wtted to the plasma or whole blood concentration versus time data using WinNonlin ® software (Version 5.1). The estimated C 0 was then used with the actual measured blood or plasma concentrations to determine the area under the blood or plasma concentration-time curve (AUC). The AUC 0-1 was calculated using the combined log-linear trapezoidal rule for data from time of dosing to the last measured concentration, plus the quotient of the last measured concentration divided by KE. Non-compartmental pharmacokinetic methods were used to calculate mean residence time (MRT by dividing AUMC 0-1 by AUC 0-1 ), clearance (CL by dividing dose by AUC 0-1 ) and volume of distribution (Vd by dividing CL by KE). Based on the cumulative urinary excretion, the fraction excreted in urine (f e by dividing the total cumulative amount of rapamycin excreted in urine ( Xu) by the dose), renal clearance (CL r by multiplying f e by CL), hepatic clearance (CL hepatic by subtracting CL r from CL), extraction ratio (ER by dividing CL hepatic by hepatic Xow (Q)). The mean hepatic blood Xow (Q) is approximately 3.22 lL/h kg [12] . Using the hematocrit in rat [12] of 0.48, this yields a mean hepatic plasma Xow of 1.74 l/h kg. Therefore, depending on plasma or blood the correct hepatic Xow (Q) needs to be employed. The estimated bioavailability could be calculated utilizing two methods: either by subtracting the ER from 1 or by using the relationships F = Q/ (Q + CL int ) and CL hepatic = (Q £ CL int )/(Q + CL int ), been CL int the intrinsic clearance.
Biodistribution study
To assess the eVect of formulation on the tissue distribution of rapamycin, rats were cannulated and intravenously administered with rapamycin dissolved in control formulation; in PEG-b-PCL formulation; or in PEG-b-PCL + -tocopherol formulation at the same dose (10 mg/kg) as pharmacokinetic studies. At 24 h after formulation injection, each animal (n = 4 for each group) was anaesthetized and exsanguinated by cardiac puncture. Brain, lungs, heart, liver, spleen, kidneys, urinary bladder, muscle as well as samples of blood and plasma were collected. Tissue samples were blotted with paper towel, washed in ice-cold saline, bottled to remove excess Xuid, weighed and rapidly frozen in liquid nitrogen, pulverized to a Wne powder with a mortar and pestle under liquid nitrogen and stored at ¡70°C until assessed for rapamycin concentration by LC/ MS analysis. Tissue to plasma concentration ratios (K p ) were calculated by dividing rapamycin concentration in each tissue by rapamycin concentration in plasma for individual animals in the biodistribution studies.
Blood distribution
To assess the eVect of formulation on the blood distribution (partition coeYcient between plasma and red blood cells) of rapamycin, rats were cannulated and intravenously administered with rapamycin dissolved in DMA, PEG, and Tween 80 (control formulation); in PEG-b-PCL formulation; or in PEG-b-PCL + -tocopherol formulation at the same dose (10 mg/kg) as pharmacokinetic studies. A total of 24 rats were used for this experiment: four rats per timepoint, two time-points (1 min and 24 h) were collected, and three formulations were dosed. One minute after dosing, the corresponding rats were anaesthetized and exsanguinated by the cannula. At 24 h post-dose, the same procedure was followed. After each collection, the blood samples were collected in heparanized tubes (Monoject, MansWeld, MA) and following centrifugation, the plasma and red blood cell (RBC) fractions were collected and stored at ¡70°C until LC/MS analysis.
Data analysis
Compiled data were presented as mean and standard error of the mean (mean § SEM). Where possible, the data were analyzed for statistical signiWcance using NCSS Statistical and Power Analysis software (NCSS, Kaysville, UT). Student's t-test was employed for unpaired samples with a value of P < 0.05 being considered statistically signiWcant.
Results
Formulation of rapamycin in PEG-b-PCL micelles
The solubilization of rapamycin in PEG-b-PCL micelles was veriWed by GPC analysis as previously described [19] . PEG-b-PCL micelles have low UV absorbance at 276 nm, the absorbance maxima of rapamycin. GPC chromatography reported rapamycin coeluted with PEG-b-PCL micelles as indicated by overlapping UV and RI chromatographs (data not shown). The resulting PEG-b-PCL micelles solubilized 10% w/w rapamycin, with a loading eYciency of ca. 90%, greater than the 50% previously reported. The increase in loading eYciency may be attributed to relatively smaller Wltration and measurement loses at larger scales utilized in this study and the use of higher quality, less polydisperse PEG-b-PCL, which we observed generally results in greater micelle formation and less aggregated material. Yamamoto et al. reported that micelles from polymers with narrower polydispersity are generally more stable [47] .
PEG-b-PCL micelles solubilizing 10% w/w rapamycin were 37 nm in diameter. Incorporation of -tocopherol increased the micelle hydrodynamic diameter to 101 nm. Nanocarriers in this size range are expected to have long circulation times and extravasate in the leaky vasculature of tumors [2] .
Pharmacokinetics of polymeric micellar rapamycin after intravenous administration
Linearity in the standard curves was demonstrated for the blood and plasma samples over the concentration range studied, and chromatograms were free of interference from endogenous components. The blood and plasma rapamycin concentration versus time proWles observed for the three formulations were similar (Figs. 2, 3, respectively) . A rapid decline in concentrations, representing a distribution phase, was observed for the Wrst 6 h in blood and 12 h in plasma after dosing for the three formulations. A slight increase in rapamycin concentration was evident at 6 h on a semi-log concentration time proWle only after the administration of control formulation, indicating the possibility of enterohepatic recycling. This was followed by an elimination phase characterized with a t 1/2 of 12-16 h for blood and 11-22 h for plasma. Rapamycin in PEG-b-PCL yielded a signiWcantly higher t 1/2 in plasma compared to rapamycin control (Table 2) .
Non-compartmental analysis of the blood and plasma concentrations showed a signiWcant change in some pharmacokinetic parameters of rapamycin in both polymeric micelles compared to control formulation (Tables 1, 2) . PEG-b-PCL micelles with the co-incorporation of -tocopherol provided higher AUC inf values in blood (57% increase) compared to control rapamycin formulation. The micelle carrier with the co-incorporation of -tocopherol decreased the total clearance (CL tot ) in blood (34%) compared to rapamycin control. The volume of distribution at the elimination phase (Vd ) in blood was found to be similar for the control and both formulations. Even though these changes in pharmacokinetic parameters, the reported mean residence time (MRT) for both formulations is not signiWcantly diVerent than the control formulation.
The mean hepatic blood Xow (Q) is approximately 3.22 l/h kg [12] . Using the hematocrit in rat [12] of 0.48, this yields a mean hepatic plasma Xow of 1.74 l/h kg. While the CL tot values in blood (0.8-1.3 l/h kg) are lower (<50%) than the mean hepatic blood Xow (3.22 l/h kg), the CL tot values in plasma (0.7-1.1 l/h kg) are closer to the mean hepatic plasma Xow (1.74 l/h kg). This can be observed by the changes in extraction ratio (ER). In the case of PEGb-PCL + -tocopherol micellar formulation there is a signiWcant reduction in CL tot in blood that correlates with lower ER values and higher estimated bioavailability (F). These observations indicate that -tocopherol induces a more sustained release of rapamycin out of the micelles in vivo (higher AUC) followed by lower degree of distribution (lower Vd ), and faster elimination (lower t 1/2 ), followed by an increase in the amount of available rapamycin to exert pharmacological activity in blood.
The terminal urine half-life of rapamycin signiWcantly increased in both micelle formulations; the PEG-b-PCL formulation increased the half-life by 6-11% while the PEG-b-PCL + -tocopherol formulation increased the halflife by more than 2-fold. Three plots are commonly employed to estimate the half-life of a compound. The amount remaining to be excreted (ARE) plot is often used to determine the accumulation of drug in urine over time. The rate of excretion plot is used in order to establish how rapidly a drug is eliminated. The third plot commonly employed in determining half-life is the blood, serum, or plasma concentration versus time plot. Furthermore, pharmacokinetic theory suggests that the slopes of the amount remaining to be excreted (ARE) plot [log ( Xu inf ¡ X u ) = log (k e X 0 /KE) ¡ KE/2.303t], the rate of excretion plot [log (dX u /dt) = log (k e X 0 ) ¡ KE/2.303t], and the serum concentration versus time plot [log C = log C 0 ¡ KE/2.303t] must be parallel because they share the same slope (KEt/2.303) and Wrst order elimination rate constant (KE). The half-life should theoretically be the same as t 1/2 = 0.693/KE. When plotted on the same graph, the three plots are parallel, in this case the ARE plot, rate plot, blood, and plasma concentrations were plotted together (Fig. 4a-c) . This indicates that the elimination rates of these three matrices, namely blood, plasma, and urine, are similar. Based on the CL renal values can be observed that rapamycin is excreted via non-renal routes and that the micelle formulation results in amount of rapamycin cleared by the kidneys.
Observations performed by blinded observers reported that immediately between 2 h post-IV dosing of control formulation the rats presented nose bleeding, disorientation, heavy breathing, slight decrease in response to sound, and 60% of the control subjects died within 24 h post-dose. The animals that received the PEG-b-PCL or PEG-b-PCL + -tocopherol formulations only presented slight nasal bleeding and 100% of the animals survived until the end of the experiment (72 h post-dose).
Biodistribution
As described in the pharmacokinetics study, marked distribution and elimination phases were noted in blood and plasma (Figs. 2, 3) . QuantiWable amounts of rapamycin were observed in all assayed tissues. The order in concentrations from highest to lowest for the rapamycin control formulation was lung > kidney > spleen > liver > urinary bladder > heart > brain > muscle > plasma > blood (Table 3) . The corresponding order for PEG-b-PCL micelle formulation was lung > spleen > kidney > liver > urinary bladder > heart > muscle > brain > plasma > blood, and for PEG-b-PCL + -tocopherol the order was urinary bladder > kidney > lung > liver > spleen > heart > muscle > brain > plasma > blood. The K p values for all the tissues were between 20 and 40, which correlates with previous observations [35] . However, signiWcantly lower Kp values (5-15) were observed in muscle and brain of animals dosed with both micelle formulations compared to control formulation. Rapamycin in PEG-b-PCL reported a statistical signiWcant decrease in concentration in blood by 27% and brain by 75%. Rapamycin in PEG-b-PCL + -tocopherol resulted in a statistically signiWcant decreased in spleen (25%) and brain (75%) concentrations, while the concentration signiWcantly increased by 69% in urinary bladder (Table 3) . The tissue to plasma concentration ratios (K p ) of rapamycin were measured 24 h post-IV administration of control and both PEG-b-PCL micelle formulations reporting quite diVerent proWles (Fig. 5) . Rapamycin in PEG-b-PCL formulation showed signiWcant lower K p values in blood, spleen, brain, and heart compared to control formulation. Similarly, rapamycin in PEG-b-PCL + -tocopherol showed signiWcant lower K p values in blood, liver, spleen, brain, muscle, lung, and heart (Table 3 ).
Blood distribution
The partition coeYcient (K d ) representing the ratio of plasma to red blood cells concentrations were calculated at 1 min (Fig. 6a ) and 24 h (Fig. 6b) after IV dosing of the diVerent rapamycin formulations. At 1 min post-dose, the formulations without and with the co-incorporation of -tocopherol have a reported increase in K d of 1.39-fold and 1.98-fold respectively compared to control formulation. The same pattern was observed at 24 h post-dosing, the K d increasing 1.31-fold and 2.11-fold for the PEG-b-PCL formulations without and with the co-incorporation of -tocopherol as compared to control formulation. This indicates the micelle formulations are changing the distribution of rapamycin in the blood, reducing the binding aYnity of the drug to RBC as expressed by the higher K d values. This would allow higher amounts of rapamycin circulating in the plasma that would be readily accessible to solid tumors. Finally, the co-incorporation of -tocopherol provided higher K d values indicating a higher distribution into the plasma.
Discussion
DiVerent clinical studies have demonstrated treatment limiting toxicities after administration of rapamycin, some of those include headaches, asthenia, mucositis, nausea, hypertriglyceridemia, thrombocytopenia, hypercholesterolemia, elevated transaminases, hyperglycemia [20] , and mild dermatological toxicities [36] . Therefore, the objective of this study was to develop novel delivery systems that can act as an eVective alternative to DMA, PEG, and Tween 80, Cremophor, or ethanol for rapamycin solubilization, control the rate of release, its disposition, increase its plasma distribution and ultimately make it safer for human administration by providing a more eVective carrier that could enable the use of lower doses.
Rapamycin pharmacokinetics have been studied extensively in diVerent species including rat, monkey, rabbit, and human. These studies have characterized rapamycin to be a drug with a relatively long half-life of more than 5 hours, with volume of distribution values that indicates a substantial proportion of the drug residing extravascularly [8, 22, 45, 52] . Rapamycin is a lipophilic compound with a partition coeYcient (X log P O/W ) of 5.77 and is highly distributed into the tissue as evidenced by the high volume of distribution value. In addition, rapamycin is highly extracted as suggested by its clearance values.
A PEG-b-PCL micelle delivery system for rapamycin was developed because of the biocompatibility of the two blocks and the thermodynamic stability of the micellar structure. The micelles increased the aqueous solubility of rapamycin to several mg/ml for PEG-b-PCL and PEGb-PCL + -tocopherol micelles, which is much higher than water solubility of rapamycin (2.6 g/ml) [34, 40] .
For carriers with long circulating properties with suYcient stability, a higher plasma concentration is hypothesized with long circulating properties [3] . The PEG-b-PCL micelle formulation with the co-incorporation of -tocopherol demonstrated signiWcant diVerences in pharmacokinetic parameters from the rapamycin control formulation (Tables 1, 2 ). The signiWcant change in AUC in blood indicates a higher degree of in vivo stability of the PEGb-PCL + -tocopherol micelle formulations. The solubilization of rapamycin in PEG-b-PCL + -tocopherol micelles led to a change in biological fate characterized by an increase in AUC and a reduction in CL tot for the solubilized drug. Although not as dramatic, These Wndings correlate with the results of the pharmacokinetics studies by Aliabadi et al. [3] , who recently reported augmented disposition of cyclosporine loaded PEG-b-PCL micelles in rats. Although clearly each drug and carrier may have a unique degree of alteration or augmentation in plasma or tissue concentrations, our observations also indicate an increase in estimated bioavailability after rapamycin was solubilized in micelles with the co-incorporation of -tocopherol. The coincorporation of -tocopherol seems to further increase the sustained release and bioavailability of rapamycin. We observed that the micelle formulation increased the Kd values indicating a higher partitioning of rapamycin into plasma. Rapamycin binds to FKBP (FK506 binding protein) in red blood cells [21] allowing for low K d values of 0.05 that has been reported to aVect the low clearance values of rapamycin out of the red blood cells [21] . Our results indicate that the encapsulation of rapamycin increase the K d values signiWcantly and that rapamycin is more rapidly cleared from plasma than RBC due to the observed lower K d values at 24 h compared to the higher K d values one minute after administration. This change in blood distribution would provide higher levels of rapamycin in plasma that could be readily accessible to solid tumors.
In the biodistribution study, the decrease in blood rapamycin concentrations seemed to coincide with a decrease in brain rapamycin concentrations for both formulations. Lower rapamycin concentrations were detected in spleen and lung, while higher concentrations were detected in urinary bladder. In general, formulation in PEG-b-PCL micelles led to no signiWcant change in the concentrations of rapamycin except for blood, brain, spleen, lung, and urinary bladder. The uptake by the brain was dramatically reduced, which is of note because rapamycin has been associated with the induction of neurotoxicity [42] . Liu et al. recently examined the distribution of PEG-b-PCL micelles in vivo [29] . Brain distribution was not reported in that study, but it is expected the blood-brain barrier would not be permeable to large molecules (>500 MW) such as micelles. Further studies are underway to determine if the micelle formulation of rapamycin might actually translate into reduced rapamycin neurotoxicity. The trend towards accumulation of rapamycin in urinary bladder after administration of rapamycin in PEG-b-PCL + -tocopherol formulation is an interesting observation that also requires further mechanistic clariWcation.
The K p value for rapamycin were lowered in blood, spleen, brain, and heart for both formulations, and additionally the K p was lowered in liver, spleen, muscle, and lung by the PEG-b-PCL + -tocopherol formulation. The high K p value after 24 h indicates the distribution of rapamycin into tissues, which can be explained by the low concentrations in plasma and reXects the rapid clearance of rapamycin from plasma.
Conclusions
The PEG-b-PCL polymeric micelle system with the coincorporation of -tocopherol allowed for the uptake, protection, and retention of the water insoluble drug rapamycin by increasing the area under the curve, at the same time reducing the total clearance while stabilizing the micellar structure in several biological matrices. The PEG-b-PCL polymeric micelle carrier with and without the co-incorporation of -tocopherol facilitated an increase in the distribution of rapamycin in plasma rather than the preferential binding of rapamycin for red blood cells by increasing the K d between 1.3 and 2.1-fold compared to a control formulation with signiWcantly less mortality. Based on our results it seems that the PEG-b-PCL micelles with co-incorporation of -tocopherol might be of the appropriate size and core/ shell properties to escape the uptake by the reticuloendothelial system and circulate for longer periods preferentially distributing in plasma versus RBCs. Further disposition studies of PEG-b-PCL polymeric micelle systems are ongoing with a variety of other hydrophobic drugs. 
